First‐in‐human trial assessing the pharmacokinetic‐pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age

The purpose of this first‐in‐human trial was to examine the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel recombinant human chorionic gonadotropin (rhCG; FE 999302, choriogonadotropin beta) to support its clinical development for various therapeutic indications. The single and...

Descripción completa

Detalles Bibliográficos
Autores principales: Broksø Kyhl, Lars‐Erik, Hesse, Christiane, Larsson, Per, Bruzelius, Katharina, Mannaerts, Bernadette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301557/
https://www.ncbi.nlm.nih.gov/pubmed/33982429
http://dx.doi.org/10.1111/cts.13037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301557/
https://www.ncbi.nlm.nih.gov/pubmed/33982429
http://dx.doi.org/10.1111/cts.13037

Ejemplares similares